[
  {
    "ts": null,
    "headline": "New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced new Phase 1b data showing encouraging antileukemic activity and a promising safety profile for bleximenib (JNJ-75276617) in combination with venetoclax and azacitidine (VEN + AZA) for the treatment of acute myeloid leukemia (AML) harboring KMT2A gene rearrangements (KMT2Ar) or NPM1 gene mutations (NPM1m). The study evaluated patients with newly diagnosed, intensive chemo-ineligible AML and relapsed or refractory AML.1 The results were featured in an",
    "url": "https://finnhub.io/api/news?id=da21608c02f02433d39361603e63297b817388d00bb9ff8a07a8190013907f22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749740400,
      "headline": "New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia",
      "id": 135220512,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new Phase 1b data showing encouraging antileukemic activity and a promising safety profile for bleximenib (JNJ-75276617) in combination with venetoclax and azacitidine (VEN + AZA) for the treatment of acute myeloid leukemia (AML) harboring KMT2A gene rearrangements (KMT2Ar) or NPM1 gene mutations (NPM1m). The study evaluated patients with newly diagnosed, intensive chemo-ineligible AML and relapsed or refractory AML.1 The results were featured in an",
      "url": "https://finnhub.io/api/news?id=da21608c02f02433d39361603e63297b817388d00bb9ff8a07a8190013907f22"
    }
  },
  {
    "ts": null,
    "headline": "Impax Global Opportunities Fund Q1 2025 Commentary",
    "summary": "The fund underperformed the benchmark during the last quarter.",
    "url": "https://finnhub.io/api/news?id=55ef6bc7cae26e7ed6f37f450a70499c47409f0159c8a81d6fd7d66fb953d33b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749738720,
      "headline": "Impax Global Opportunities Fund Q1 2025 Commentary",
      "id": 135222131,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2149339098/image_2149339098.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The fund underperformed the benchmark during the last quarter.",
      "url": "https://finnhub.io/api/news?id=55ef6bc7cae26e7ed6f37f450a70499c47409f0159c8a81d6fd7d66fb953d33b"
    }
  },
  {
    "ts": null,
    "headline": "New Results for Johnson & Johnson's Bleximenib Demonstrating Antileukemic Activity in Combination with Venetoclax and Azacitidine for Acute Myeloid Leukemia",
    "summary": "Johnson & Johnson announced new Phase 1b data showing encouraging antileukemic activity and a promising safety profile for bleximenib in combination with venetoclax and azacitidine for the treatment...",
    "url": "https://finnhub.io/api/news?id=d9d29fbd00378ad173b0e4c8a5cadd21dd3bbf76c9a6ad79946931bd829a88cb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749737133,
      "headline": "New Results for Johnson & Johnson's Bleximenib Demonstrating Antileukemic Activity in Combination with Venetoclax and Azacitidine for Acute Myeloid Leukemia",
      "id": 135221284,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced new Phase 1b data showing encouraging antileukemic activity and a promising safety profile for bleximenib in combination with venetoclax and azacitidine for the treatment...",
      "url": "https://finnhub.io/api/news?id=d9d29fbd00378ad173b0e4c8a5cadd21dd3bbf76c9a6ad79946931bd829a88cb"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson : Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison",
    "summary": "Media contact: Jenni Mildon jmildon@its.jnj.com +44 7920 418 552 Investor contact: ...",
    "url": "https://finnhub.io/api/news?id=a1bbbff37a96907c468ff3001625fb55cf8b7b3ac456e00456f1ebd48db8bc2c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749731592,
      "headline": "Johnson & Johnson : Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison",
      "id": 135216009,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Media contact: Jenni Mildon jmildon@its.jnj.com +44 7920 418 552 Investor contact: ...",
      "url": "https://finnhub.io/api/news?id=a1bbbff37a96907c468ff3001625fb55cf8b7b3ac456e00456f1ebd48db8bc2c"
    }
  },
  {
    "ts": null,
    "headline": "Kennedy Remakes CDC Committee in His Own Vaccine-Skeptical Image",
    "summary": "Kennedy Remakes CDC Committee in His Own Vaccine-Skeptical Image",
    "url": "https://finnhub.io/api/news?id=0b382baa996a937fe2e5e05f64a5a3492e11fa48447180bc5d19353b14653c11",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749729420,
      "headline": "Kennedy Remakes CDC Committee in His Own Vaccine-Skeptical Image",
      "id": 135214634,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Kennedy Remakes CDC Committee in His Own Vaccine-Skeptical Image",
      "url": "https://finnhub.io/api/news?id=0b382baa996a937fe2e5e05f64a5a3492e11fa48447180bc5d19353b14653c11"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson - New data show TREMFYA is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis",
    "summary": "BARCELONA - Johnson & Johnson announced findings from the Phase 3b APEX study showing that TREMFYA significantly reduced both signs and symptoms of active psoriatic arthritis and inhibited...",
    "url": "https://finnhub.io/api/news?id=f58e451ebb5655e329a91055053096a96aeb9f4f55ce2ffc31ec1b916bdfc252",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749724075,
      "headline": "Johnson & Johnson - New data show TREMFYA is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis",
      "id": 135212838,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "BARCELONA - Johnson & Johnson announced findings from the Phase 3b APEX study showing that TREMFYA significantly reduced both signs and symptoms of active psoriatic arthritis and inhibited...",
      "url": "https://finnhub.io/api/news?id=f58e451ebb5655e329a91055053096a96aeb9f4f55ce2ffc31ec1b916bdfc252"
    }
  },
  {
    "ts": null,
    "headline": "Understanding XLV: A Sector ETF Focused On U.S. Healthcare Giants",
    "summary": "The Healthcare Select Sector SPDR Fund ETF is a sector ETF offering exposure to large-cap U.S. healthcare companies. Learn more about XLV here.",
    "url": "https://finnhub.io/api/news?id=3395881387b067938f0ba799e92a4638be4c4545682cad63079c09828b6b9e0b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749722400,
      "headline": "Understanding XLV: A Sector ETF Focused On U.S. Healthcare Giants",
      "id": 135212617,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1432883724/image_1432883724.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The Healthcare Select Sector SPDR Fund ETF is a sector ETF offering exposure to large-cap U.S. healthcare companies. Learn more about XLV here.",
      "url": "https://finnhub.io/api/news?id=3395881387b067938f0ba799e92a4638be4c4545682cad63079c09828b6b9e0b"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial",
    "summary": "The antibody improved joint and skin symptoms in active PsA patients.",
    "url": "https://finnhub.io/api/news?id=fd4edbc693b13eae7358acab7a4b7b432a45d3a1b5f9487734e0b2b7eaac143d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749721226,
      "headline": "J&J’s Tremfya reduces active psoriatic arthritis symptoms in Phase IIIb trial",
      "id": 135211663,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The antibody improved joint and skin symptoms in active PsA patients.",
      "url": "https://finnhub.io/api/news?id=fd4edbc693b13eae7358acab7a4b7b432a45d3a1b5f9487734e0b2b7eaac143d"
    }
  },
  {
    "ts": null,
    "headline": "Trump Wants Cheaper Drugs Like Europe Has. How It Works.",
    "summary": "Trump Wants Cheaper Drugs Like Europe Has. How It Works.",
    "url": "https://finnhub.io/api/news?id=9f698653c1a2df4372c8b3a698e0dd3936c283e60cbe2c806d4d889e2bd8eafd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749720060,
      "headline": "Trump Wants Cheaper Drugs Like Europe Has. How It Works.",
      "id": 135214300,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Trump Wants Cheaper Drugs Like Europe Has. How It Works.",
      "url": "https://finnhub.io/api/news?id=9f698653c1a2df4372c8b3a698e0dd3936c283e60cbe2c806d4d889e2bd8eafd"
    }
  },
  {
    "ts": null,
    "headline": "ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze",
    "summary": "ImmunityBioâs Anktiva holds bladder cancer promise despite FDA hurdles, while its lymphopenia treatment could unlock major upside. Learn why IBRX stock is a buy.",
    "url": "https://finnhub.io/api/news?id=75e7e19b4204e3e6b1b0d4a3ec11a595e1fe670d60854e9cf5ec8237b5595df1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749719343,
      "headline": "ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze",
      "id": 135212041,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1623197589/image_1623197589.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "ImmunityBioâs Anktiva holds bladder cancer promise despite FDA hurdles, while its lymphopenia treatment could unlock major upside. Learn why IBRX stock is a buy.",
      "url": "https://finnhub.io/api/news?id=75e7e19b4204e3e6b1b0d4a3ec11a595e1fe670d60854e9cf5ec8237b5595df1"
    }
  },
  {
    "ts": null,
    "headline": "J&J: Imbruvica shows promise in lymphocytic leukemia",
    "summary": "Johnson & Johnson announces that the combination of Imbruvica and venetoclax is more effective than the combination of acalabrutinib and venetoclaxnétoclax, in the treatment of chronic lymphocytic...",
    "url": "https://finnhub.io/api/news?id=85a38f17001e2214b70fd7a9007a55e3b99b9fc1a7a64fca66f20e0f0b1b951e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749718311,
      "headline": "J&J: Imbruvica shows promise in lymphocytic leukemia",
      "id": 135211834,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announces that the combination of Imbruvica and venetoclax is more effective than the combination of acalabrutinib and venetoclaxnétoclax, in the treatment of chronic lymphocytic...",
      "url": "https://finnhub.io/api/news?id=85a38f17001e2214b70fd7a9007a55e3b99b9fc1a7a64fca66f20e0f0b1b951e"
    }
  },
  {
    "ts": null,
    "headline": "Significant Efficacy Benefit Of IMBRUVICA Plus Venetoclax Versus Acalabrutinib Plus Venetoclax In Frontline Treatment Of Patients With Chronic Lymphocytic Leukaemia Suggested By Indirect Treatment Comparison",
    "summary": "Johnson & Johnson: * SIGNIFICANT EFFICACY BENEFIT OF IMBRUVICA® PLUSVENETOCLAX VERSUS ACALABRUTINIB PLUS VENETOCLAX IN FRONTLINETREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC...",
    "url": "https://finnhub.io/api/news?id=90e34768115fd87933e1e77c54e62d2135156992df7eec75f17894f2aa83ca00",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749717209,
      "headline": "Significant Efficacy Benefit Of IMBRUVICA Plus Venetoclax Versus Acalabrutinib Plus Venetoclax In Frontline Treatment Of Patients With Chronic Lymphocytic Leukaemia Suggested By Indirect Treatment Comparison",
      "id": 135211645,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson: * SIGNIFICANT EFFICACY BENEFIT OF IMBRUVICA® PLUSVENETOCLAX VERSUS ACALABRUTINIB PLUS VENETOCLAX IN FRONTLINETREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC...",
      "url": "https://finnhub.io/api/news?id=90e34768115fd87933e1e77c54e62d2135156992df7eec75f17894f2aa83ca00"
    }
  }
]